The present invention relates to a composition for detecting a target substance based on proximity proteolysis reaction and a method for detecting a target substance using the same, and more specifically, to a method for detecting a target substance including binding a first binder and a second binder to a target substance, hybridizing ssDNA linked to the first binder with ssDNA linked to a protease, hybridizing ssDNA linked to the second binder with ssDNA linked to an enzyme source (zymogen), and detecting a signal generated by a proximity proteolysis reaction between the protease and the enzyme source.
Various biological molecules, including nucleic acids, proteins, and small molecules, show the physiological state of organisms and act as biomarkers of diseases. Assays for detecting or quantifying biological molecules are essential to the clinical field and various assays have been developed (Wu, L. & Qu, X. Chem Soc Rev 44, 2963-2997, doi:10.1039/c4cs00370e (2015); Sanavio, B. & Krol, S. Front Bioeng Biotechnol 3, 20, doi:10.3389/fbio e.2015.00020 (2015)). Simple homogeneous assays for nucleic acids using specific hybridization of DNA strands based on the Watson-Crick base pairing principle have been developed, contributing to the early detection of pathogens and abnormal cells. On the other hand, heterogenous assays involving solid surfaces, such as enzyme-linked immunosorbent assay (ELISA) and modified versions thereof, have been standards for detecting proteins and small molecules for decades (Zhang, S., et al., Analyst 139, 439-445, doi:10.1039/c3an01835k (2014)). Although these methods meet the essential features of diagnostic tools, such as robustness, sensitivity, and specificity, the typical procedure for these assays includes a plurality of steps for target binding and elimination of non-specific interactions, typically requires trained personnel or automated instruments, and takes more than one day. Therefore, heterogeneous assays are not suitable as point-of-care methods. Recently, efforts have been made to research and develop point-of-care tests that contribute to early diagnosis of diseases in resource-limited environments.
Typically, a method optimized for point-of-care diagnosis is an analysis performed in a homogeneous phase. Various strategies have been suggested for designing homologous assays to detect proteins and small molecules, including inducing molecular assembly in the presence of a target molecule (Liu, H. et al. Theranostics 6, 54-64, doi:10.7150/thno.13159 (2016); Hwang, B. B., et al., Commun Biol 3, 8, doi:10.1038/s42003-019-0723-9 (2020)). The colocalization of the sensor generates a detectable signal, allowing the assay to be performed in the liquid phase with minimal background signal. Forster resonance energy transfer pairs and split proteins were used to monitor molecular interactions. When these molecules are covalently or physically linked to two binders that target independent regions of the molecule, the resulting molecules can detect the target in a homogeneous phase. The reaction rate can be improved by locating the reactants close to each other to increase effective concentrations thereof. This principle of reaction facilitation based on proximity has been used to design chemical and biological reactions to analyze various molecules and molecular interactions such as proteins, antibodies, and nucleic acids.
In this regard, a nucleic acid analysis method with simplicity and high sensitivity based on a novel proximity-enhancing reaction called “proximity proteolysis reaction (PPR)” is known (Park, H. J. & Yoo, T. H. ACS Sens 3, 2066-2070, doi:10.1021/acssensors.8b00821 (2018)), but there has been no report on a method for detecting target substances such as proteins and small molecules using this method.
Accordingly, as a result of diligent efforts to detect target substances such as proteins and small molecules with high sensitivity even at low concentrations, the present inventors have found that a target substance may be easily and quickly detected even at a sub-nanomolar target substance concentration when the target substance is detected using a first binder and a second binder binding to the target substance, and the proximity proteolytic reaction between a protease and zymogen linked through hybridization between each binder and ssDNA, thereby completing the present invention.
The information disclosed in this Background section is provided only for enhancement of understanding of the background of the present invention, and therefore it may not include information that forms the prior art that is already obvious to those skilled in the art.
Therefore, it is an object of the present invention to provide a composition for detecting a target substance capable of rapidly detecting target materials such as proteins and small molecules with high sensitivity, and a method for detecting a target substance using the same.
In accordance with one aspect of the present invention, the above and other objects can be accomplished by the provision of a composition for detecting a target substance including i) a first DNA-first binder conjugate in which a first DNA is linked to a first binder, ii) a first DNA'-protease conjugate in which a first DNA′ having a sequence complementary to the first DNA is linked to a protease, iii) a second DNA-second binder conjugate in which a second DNA is linked to a second binder, iv) a second DNA′-zymogen conjugate in which a second DNA′ having a sequence complementary to the second DNA is linked to an enzyme source (zymogen), and v) a substrate specific to the enzyme source.
In accordance with another aspect of the present invention, provided is a method of detecting a target substance including (a) mixing the composition with a sample containing a target substance, (b) binding the target substance to the first binder of the first DNA-first binder conjugate, binding the target substance to the second binder of the second DNA-second binder conjugate, hybridizing the first DNA linked to the first binder with the first DNA′ linked to a protease, and hybridizing the second DNA linked to the second binder with the second DNA′ linked to an enzyme source (zymogen), and (c) detecting a signal generated by a proximity proteolysis reaction between the first DNA′-protease conjugate hybridized with the first DNA of the first binder and the second DNA′-zymogen conjugate hybridized with the second DNA of the second binder.
In accordance with another aspect of the present invention, provided is a method of detecting a small molecule including (a) mixing a composition further containing an anti-small molecule with a sample containing a small molecule, (b) hybridizing the first DNA linked to the first binder with the first DNA′ linked to a protease and hybridizing the second DNA linked to the second binder with the second DNA′ linked to an enzyme source (zymogen), and (c) detecting whether or not the small molecule is present depending on the presence or absence of a signal generated by a proximity proteolysis reaction between the hybridized first DNA′-protease conjugate and the hybridized second DNA′-zymogen conjugate.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as appreciated by those skilled in the field to which the present invention pertains. In general, the nomenclature used herein is well-known in the art and is ordinarily used.
In the present invention, a first DNA and a second DNA were linked to a first binder and a second binder binding to a target substance, respectively, a first DNA′ and a second DNA′ having sequences complementary to the first DNA and the second DNA were linked to a protease and a zymogen, respectively, and then the target substance was detected using a composition containing the four ssDNA-conjugates and a substrate specific to the enzyme source (zymogen) (Example 1).
Accordingly, in one aspect, the present invention is directed to a composition for detecting a target substance containing i) a first DNA-first binder conjugate in which a first DNA is linked to a first binder; ii) a first DNA′-protease conjugate in which a first DNA′ having a sequence complementary to the first DNA is linked to a protease; iii) a second DNA-second binder conjugate in which a second DNA is linked to a second binder; iv) a second DNA′-zymogen conjugate in which a second DNA′ having a sequence complementary to the second DNA is linked to an enzyme source (zymogen); and v) a substrate specific to the enzyme source.
In the present invention, the first binder and the second binder may be the same as or different from each other.
In the present invention, the binder may be an antibody, an aptamer, an antigen, a small molecule, or a protein that is capable of binding to the target substance.
In the present invention, the antibody may be trastuzumab, pertuzumab or anti-cTnI antibody, and the antigen may be digoxigenin (Dig) or human chorionic gonadotropin (hCG).
In the present invention, the target substance may be an antigen, antibody, small molecule or protein.
In the present invention, the antigen may be HER2, cTnI or thrombin, and the antibody may be an anti-digoxigenin (Dig) antibody or an anti-human chorionic gonadotropin (hCG) antibody.
In the present invention, when the target substance is HER2, the first binder is trastuzumab and the second binder is pertuzumab (Examples 2 and 3).
In the present invention, when the target substance is cardiac troponin I (cTnI), the first binder is a first anti-cTnI antibody and the second binder is a second anti-cTnI antibody (Example 4).
In the present invention, when the target substance is thrombin, the first binder is a first aptamer capable of binding to thrombin and the second binder is a second aptamer capable of binding to thrombin (Example 5).
In the present invention, the first aptamer is represented by SEQ ID NO: 7, the second aptamer is represented by SEQ ID NO: 8, the first DNA is represented by SEQ ID NO: 5, and the second DNA is represented by SEQ ID NO: 6 (Table 2).
In the present invention, when the target substance is an anti-digoxigenin (Dig) antibody, the first binder and the second binder are digoxigenin (Dig) (Example 7).
In the present invention, when the target substance is an anti-human chorionic gonadotropin (hCG) antibody, the first binder and the second binder are human chorionic gonadotropin (hCG) (Example 7).
The affinity of the binder for the target substance and the ratio of TEVP or BLZ to the binder may affect assay performance. The dissociation constant (Ka) of the binders to HER2 and thrombin have been reported (trastuzumab to HER2: 173 pM; pertuzumab to HER2: 32 pM; Aptamer1 to thrombin: 102.6 nM; Aptamer2 to thrombin: 0.5 nM) (Deng, B. et al. Anal Chim Acta 837, 1-15, do i:10.1016/j.aca.2014.04.055 (2014); Komarova, T. V. et al. Sci Rep 9, 16168, doi:10.1038/s41598-019-52507-9 (2019)), the number of ssDNA molecules covalently linked to the binder is different, 1 (thrombin aptamer) to 4 (trastuzumab and pertuzumab). In order to offset the difference, a method for detecting HER2 and thrombin was developed by optimizing the concentrations of the four components (TEVP-first DNA′, BLZ-second DNA′, first binder-first DNA, and second binder-second DNA). Under each selected condition, both assays showed similar performance in detection range and LOD. In addition, other binders (anti-cTnI antibody, anti-Dig antibody, and polyclonal anti-hCG antibody) having no reported affinity may be applied to PPR-based homogeneous analysis, by controlling the concentration of the components thereof. These results suggest that many available binders with Kd values in the nanomolar range are useful for PPR-based homogeneous assays. In addition, since PPR-based homogeneous assays are performed in a module manner, it is easy for those skilled in the art to apply the homogeneous assay of the present invention to other types of target substances.
The binder to the target substance was linked to TEVP and BLZ through hybridization between the two DNA strands, instead of direct conjugation. By conjugating binders with ssDNA through this approach, two types of binders can be used: proteins (including antibodies) and aptamers. In addition, since there is no need to prepare the TEVP-first binder and the BLZ-second binder prior to mixing with the sample, the assay may be performed in a one-step manner. Since DNA oligomers may be synthesized to contain specific functional groups for chemical reactions, various pathways for generating DNA and conjugates have been reported (Dovgan, I., et al., Bioconjug Chem 30, 2483-2501, doi:10.1021/acs.bioconjchem.9b00306 (2019)). Further defined ssDNA-binder conjugates can be produced using other chemical reactions, in addition to NHS-amine coupling, which contribute to the robustness and reproducibility of the assay.
Detecting molecular interactions such as protein-protein interactions may be performed using binders that target different molecules. In addition, since binders such as antibodies and aptamers have been reported to recognize post-translational modifications of proteins (Diaz-Fernandez, A. et al. Chemical Science 11, 9402-9413, doi:10.1039/d0sc00209g (2020)), such modifications can be detected in the target protein. In addition, using a reported binder for modified nucleic acids (Bhattacharjee, R., et al., Analyst 143, 4802-4818, doi: 10.1039/c8an01348a (2018)), epigenetic modifications of chromosomes can be detected at specific positions.
In the present invention, when the target substance is a small molecule, the first binder and the second binder may be the same small molecule as the target substance and the composition further contains an anti-small molecule antibody.
In the present invention, when the small molecule is digoxigenin (Dig), the anti-small molecule antibody may be an anti-Dig antibody (Example 6).
In the present invention, the first DNA may be represented by SEQ ID NO: 1 and the second DNA may be represented by SEQ ID NO: 2 (Table 1).
In the present invention, the protease may be a tobacco etch virus (TEV) protease, a hepatitis C virus (HCV) protease, a tobacco vein mottling virus (TVMV) protease or a human rhinovirus (HRV) 3c protease, but is not limited thereto.
In the present invention, the enzyme source may have a configuration in which an enzyme is linked to an enzyme activity inhibitor protein through a peptide linker that is cleavable by the protease.
In the present invention, the enzyme source may be β-lactamase zymogen.
In the present invention, the substrate may be a
chromogenic substrate and the chromogenic substrate may be CENTA™, but is not limited thereto.
In another aspect, the present invention is directed to a method of detecting a target substance including (a) mixing the composition with a sample containing a target substance, (b) binding the target substance to the first binder of the first DNA-first binder conjugate, binding the target substance to the second binder of the second DNA-second binder conjugate, hybridizing the first DNA linked to the first binder with the first DNA′ linked to a protease, and hybridizing the second DNA linked to the second binder with the second DNA′ linked to an enzyme source (zymogen), and (c) detecting a signal generated by a proximity proteolysis reaction between the first DNA′-protease conjugate hybridized with the first DNA of the first binder and the second DNA′-zymogen conjugate hybridized with the second DNA of the second binder.
Homogeneous analytical procedures for proteins and small molecules may be performed in a mix-and-read format at a constant temperature based on the PPR-based analytical principle. In addition, the catalytic conversion of CENTA™ by β-lactamase enables the detection of target substances at sub-nanomolar concentrations based on absorbance signals.
In the present invention, the enzyme source may have a configuration in which the enzyme is linked to the enzyme activity inhibitor protein through a peptide linker that is cleavable by the protease.
In the present invention, the proximal proteolysis reaction in step (d) is performed by cleaving the peptide linker by the protease to split the enzyme source into an enzyme and an enzyme activity inhibitor protein to thereby activate the enzyme, and hydrolyzing the substrate by the activated enzyme to generate a signal.
In the present invention, the protease may be a tobacco etch virus (TEV) protease, a hepatitis C virus (HCV) protease, a tobacco vein mottling virus (TVMV) protease, or a human rhinovirus (HRV) 3c protease, but is not limited thereto.
In the present invention, the enzyme source may be β-lactamase zymogen.
In the present invention, the substrate may be a chromogenic substrate and the chromogenic substrate may be CENTA™, but is not limited thereto.
In the present invention, the enzyme source is β-lactamase zymogen, the substrate is CENTA™and the change in absorbance at 405 nm when the sample contains the target substance is greater than the change in absorbance when the sample does not contain the target substance.
In the present invention, the enzyme source is β-lactamase zymogen, the substrate is nitrocefin, and the sample generates a red signal when it contains the target substance and generates a yellow signal when it does not contain the target substance.
In another aspect, the present invention is directed to a method of detecting a small molecule including (a) mixing the composition further containing the anti-small molecule antibody with a sample containing a target substance, (b) hybridizing the first DNA linked to the first binder with the first DNA′ linked to a protease and hybridizing the second DNA linked to the second binder with the second DNA′ linked to an enzyme source (zymogen), and (c) detecting whether or not the small molecule is present depending on the presence or absence of a signal generated by a proximity proteolysis reaction between the hybridized first DNA′-protease conjugate and the hybridized second DNA′-zymogen conjugate.
In the present invention, when the sample in step (a) contains a small molecule, the small molecule binds to an anti-small molecule antibody, so that the proximity proteolysis reaction in step (c) does not occur and there is no signal generated by the reaction (Example 6,
In the present invention, when the sample in step (a) does not contain a small molecule, the anti-small molecule antibody binds to the first binder of the first DNA-first binder conjugate and to the second binder of the second DNA-second binder conjugate, so that a signal is generated by the proximity proteolysis reaction between the hybridized first DNA′-protease conjugate and the hybridized second DNA′-zymogen conjugate in step (c) (Example 6,
Descriptions of components related to the first binder, the second binder, the target substance, the first DNA, and the second DNA used in the method for detecting the target substance or small molecule according to the present invention may be equally applied to the method.
Hereinafter, the present invention will be described in more detail with reference to examples. However, it will be obvious to those skilled in the art that these examples are provided only for illustration of the present invention, and should not be construed as limiting the scope of the present invention.
Proteases and zymogens are physically linked to binders such as antibodies, aptamers, and antigens for analysis using specific and robust hybridization between complementary ssDNA molecules. A pair of a tobacco etch virus protease (TEVP) and β-lactamase zymogen (BLZ) were used for proteolysis. TEVP has been widely used in recombinant protein engineering due to high specificity thereof. BLZ was previously designed to be activated by TEVP (
In a homogeneous assay to detect the target substance, samples were mixed with four conjugates (TEVP-first DNA′, BLZ-second DNA′, first binder-first DNA agent, second binder-second DNA) and 400 mM CENTA™ (EMD Millipore, USA) in a reaction buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 40 mM MgCl2, 10 mM DTT, 0.5% (w/v) BSA, and pH 7.4). Hydrolysis of CENTA™ by β-lactamase was monitored by measuring absorbance (A405) at 405 nm using a plate reader (synergy HT multi-detection reader; BioTek Instruments, USA) at 37° C. for 1 hour. The absorbance signal (ΔAbs=A405 at 60 min−A405 at 1 min) was plotted as a function of the concentration of the target substance. All experiments were performed at least three times and the limit of detection (LOD) was calculated as the sum of the mean ΔAbs of the blank and three times the standard deviation. In the competitive immunoassay for small molecule detection, an antibody against the target was further contained in the reaction solution. The following proteins were used as targets: HER2 (extracellular domain; 10004-H08H; Sino Biological, China), cTnI protein (ab207624; Abcam, United Kingdom), thrombin (ab62452; Abcam), digoxigenin (D9026; Sigma, USA), digoxigenin polyclonal antibody (PA1-85378; Thermo Fisher Scientific, USA) and hCG monoclonal antibody (MA5-14680; Thermo Fisher Scientific).
TEVP and BLZ were linked to binders using nucleic acid hybridization rather than direct conjugation in order to develop a method applicable to various binders. For site-specific conjugation between BLZ and the second DNA′ (Table 1), a bifunctional linker (N-hydroxysuccinimide ester-(polyethyleneglycol)4-dibenzocyclooctyne; DBCO-PEG4-NHS ester) was used (
The production of binder-ssDNA molecules differs depending on the binder and methods for each case will be described later in the following Example. The sequence of the ssDNA molecule was designed to provide strong and specific interactions between the strands under assay conditions and was analyzed using the nucleic acid package.
A homologous assay based on PPR was performed to detect the ectodomain of human epidermal growth factor receptor-2 (HER2) (
Whether or not an assay generated a specific signal for the ectodomain of HER2 was determined using the antibody-ssDNA conjugate (
HER2 is a membrane protein and the expression thereof is usually analyzed using flow cytometry or immunohistochemical staining including a plurality of steps including immobilization and repeated washing. In the present invention, a one-step analysis procedure for detecting HER2 was performed in several breast cancer cell lines having various expression levels of HER2 (
A number of antibodies against various antigens have already been constructed or developed and homogeneous assays based on PPR using the antibodies as binders have been developed. Cardiac troponin I (cTnI) in the blood acts as an essential biomarker for heart damage and protein detection methods for detecting the same have been researched. In the present invention, PPR-based homogeneous assays for detecting cTnI using two commercially available anti-cTnI antibodies that recognize distinct epitopes corresponding to amino acids 23-29 (anti-cTnI Ab1) and 41-49 (anti-cTnI Ab2) of cTnI were developed. In accordance with the procedure used for the anti-HER2 antibody, the antibody was conjugated with ssDNA (first DNA and second DNA) to form anti-cTnI Ab1-first DNA and anti-cTnI Ab2-second DNA (
Aptamers consisting of nucleic acids have been developed to have affinity for various molecules. Compared to general antibodies, aptamers have advantages such as small size, high stability, and production through chemical synthesis. In the present invention, the ssDNA-binder could be synthesized without additional conjugation and purification steps using an aptamer as a binder in the analysis. Two aptamers reported to bind to separate regions of human α-thrombin (15-mer and 27-mer DNA) were used. The 15-mer thrombin aptamer (aptamer 1) interacts with the fibrinogen-recognition exosite, whereas the 27-mer aptamer (aptamer 2) binds to the heparin-binding exosite (
The specificity of three PPR-based homogeneous assays developed to detect HER2, cTnI and thrombin was evaluated. Signals differed significantly from the background only when the binders matched the targets thereof (
GGTTGGTGTGGTTGGttttttT
AGTCCGTGGTAGGGCAGGTTGG
GGTGACttttttGAATGCTGGT
Unlike biological macromolecules such as proteins, with a few exceptions, finding pairs of binders that simultaneously interact with small molecules is generally limited (H Ueda, K. T., et al., Nat Biotechnol 14, 1714-1718, doi:10.1038/nbt1296-1714. (1996)). Therefore, competition-based assays such as competitive ELISA have been developed to detect low molecular weight targets. A competitive homologous assay to detect small molecules using a PPR-based assay format was developed (
The concentrations of antibodies against target antigens provide essential information for understanding the clinical response of therapeutic agents and diagnosing infectious and autoimmune diseases. In addition, the antibody titer of the medium is a key parameter controlling the production process of therapeutic antibodies. Reagents (Dig-first DNA and Dig-second DNA) generated for the competitive homologous assay for Digoxin were used to detect anti-Dig antibodies in the samples (
The size of the antigen may affect the proteolytic reaction between TVEP and BLZ combined with the antibody, and in the present invention, the method of the present invention was applied to an antibody against a protein antigen (human chorionic gonadotropin, hCG,
E. coli BL21 (DE3) was transfected with TEVP-SpyTag, a plasmid (pSPEL515) encoding a fusion protein composed of TEVP and SpyTag. Cultures grown in 2×YT medium at 37° C. were induced with 0.4 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) at an optical density (OD600) of 0.5 and then further grown at 25° C. for 8 hours. The cells were collected by centrifugation and proteins (containing His6 tag) were purified using Ni-NTA resin (Clontech, Japan) in accordance with the manufacturer's instructions. Purified TEVP-SpyTag protein was stored in TEVP storage buffer (50 mM Tris-HCl, 10 mM NaCl, 0.5 mM EDTA, and 40% (v/v) glycerol; pH 8.0) at −20° C.
E. coli BL21 (DE3) was transfected with plasmids expressing SpyCatcher-AzF and the b-lactamase zymogen-azidophenylalanine (BLZ-AzF) SpyCatcher-AzF (pSPEL517) or BLZ-AzF (pSPEL427) along with two other plasmids: first, an orthogonal pair of aminoacyl-tRNA synthetase and tRNA from Methanococcus jannaschii were encoded to incorporate AzF in response to the TAG codon and second, E. coli prolyl-tRNA synthetase (ProRS) was overexpressed to inhibit misincorporation of AzF into the Pro position of the protein. Cells were grown to an OD600 of 0.5 at 37° C. in 2×YT and 0.2% L-arabinose and 50 nM anhydrous tetracycline were added thereto to induce expression of orthogonal pairs and ProRS. When the OD600 reached 1.0, 1 mM AzF and 0.4 mM IPTG were added to the culture to induce expression of SpyCatcher-AzF or BLZ-AzF. Cells expressing SpyCatcher-AzF were further incubated at 30° C. for 8 hours and cells expressing BLZ-AzF were incubated at 25° C. overnight. The protein has a His6 tag and was purified on Ni-NTA resin in accordance with the manufacturer's instructions. BLZ-AzF was expressed in the periplasmic space and the purification procedure was applied to the periplasmic fraction. Purified proteins were stored at −20° C. in PBS containing 20% (v/v) glycerol.
IgG (Trastuzumab and Pertuzumab) and Human Chorionic Gonadotropin (hCG)
For the construction of expression vectors, synthetic genes encoding trastuzumab, pertuzumab and hCG including Kozak sequences were cloned into pcDNA 3.1 at NotI and XhoI sites. The names of the constructed plasmid including each plasmid and protein sequences are shown in Table 3. Proteins were produced in the HEK293F cell line maintained in FreeStyle 293 expression medium (Gibco, Thermo Fisher Scientific, USA). For protein expression, 2×106 cells were transfected with 250 μg of the expression vector encoding the protein sequence using 750 μg of polyethyleneimine (Polysciences, USA) in 200 mL of medium. The cells were incubated for 5 to 7 days, the supernatant was collected using centrifugation, each antibody was purified on CaptivA protein A affinity resin (Repligen, USA), and hCG was purified on NI-NTA resin in accordance with the instructions provided by the manufacturer. Each purified protein was stored at −20° C. in PBS.
The concentration of the purified protein was determined by measuring the absorbance at 280 nm and the extinction coefficient was calculated through the ProtParam site (http://web.expasy.org/protparam/).
Conjugation of ssDNA and protein through a Bifunctional Linker (N-hydroxysuccinimide ester-(polyethylene glycol)4-dibenzocyclooctyne; DBCO-PEG4-NHS ester)
Single-stranded DNA functionalized with 5′ amine groups (DNA1′ or DNA2′) was mixed with a 20-fold molar excess of the DBCO-PEG4-NHS ester. The reaction mixture of PBS was incubated at 25° C. in the dark for 2 hours. The modified ssDNA was purified by 75% ethanol precipitation to remove unreacted linkers and the pellet was resuspended in PBS for storage at −20° C. 5′-modified DNA2′ (DNA2′-DBCO) and BLZ-AzF were mixed at a molar ratio of 5:1 for a strain-promoted azide-alkyne reaction between DBCO and azide. The reaction mixture in PBS was incubated at 4° C. overnight. The product was first purified by anion exchange chromatography on a HiTrap Q column (GE Healthcare Life Sciences, USA) to remove unconjugated protein, and the conjugate was eluted with a gradient of 0.2 to 1.0 M NaCl. Then, the purified fraction was subjected to gel filtration chromatography on Superdex 75 10/300 GL (GE Healthcare Life Sciences, USA) to remove unreacted DNA2′-DBCO. Purified BLZ-DNA2 conjugates were stored at −20° C. in PBS containing 20% (v/v) glycerol. Conjugation of SpyCatcher-AzF with DNA1′-DBCO was performed in the same manner as in BLZ-DNA2′ and the product was purified using a HiTrap Q column with gradient elution from 0.2 to 1.0 M NaCl. The purified solution contains unreacted DNA1′-DBCO that does not interfere with the subsequent reaction between SpyCatcher and SpyTag. Finally, partially purified SpyCatcher-DNA1′ was incubated along with TEVP-SpyTag for spontaneous isopeptide bond formation. Unreacted SpyCatcher-DNA1′ was removed using a Step-Tactin resin (IBA Lifesciences, Germany) in accordance with the manufacturer's instructions. The TEVP-SpyTag protein has a Strep tag. Purified BLZ-DNA2 conjugates were stored at −20° C. in TEVP storage buffer.
Conjugation of ssDNA and Protein via bis-N-hydroxysuccinimide (NHS) Linker
The amine-functionalized ssDNA (DNA1 or DNA2) synthesized in Bioneer Co. (Korea) was mixed with a 200-fold molar excess of the Bis-NHS ester linker and the reaction mixture was incubated in PBS at 4° C. for 1 hour. The modified ssDNA was precipitated with 75% ethanol to remove unreacted linkers and the pellet was resuspended in PBS. ssDNA having an NHS ester group was reacted with a trastuzumab, pertuzumab, anti-cardiac troponin I (cTnI) antibody (ab92408, ab10231; Abcam, United Kingdom) or hCG at 4° C. for 16 hours. The ratio of ssDNA to protein for the conjugation reaction was 25:1 for the trastuzumab, 45:1 for the pertuzumab, 55:1 for the anti-cTnI antibody, and 30:1 for the hCG. The conjugate was purified by gel filtration chromatography on Superdex 200 Increase 10/300 GL (GE Healthcare Life Sciences, USA) to remove unreacted ssDNA. Purified conjugates were stored at -20° C. in PBS.
Conjugation of ssDNA and ε-(digoxigenin-3-0-acetamido)caproic acid N-hydroxysuccinimide Ester (Dig-NHS Ester)
Amine-functionalized ssDNA (DNA1 or DNA2) was incubated along with a 20-fold molar excess of Dig-NHS ester (Sigma, USA) in PBS at 25° C. for 2 hours. Dig-modified ssDNA was precipitated with 75% ethanol to remove unreacted Dig-NHS esters. The pellet was resuspended in PBS and the solution was stored at −20° C. The conjugate concentration was calculated from the absorbance measured at 260 nm and the extinction coefficient calculated on the MOLBIOTOOLS site (http://www.molbiotools.com/dnacalculator.html).
Determination of ssDNA-Protein Conjugate Concentration
The concentration of each conjugate was calculated
by measuring absorbance at 260 and 280 nm as follows (using extinction coefficients calculated from MOLBIOTOOLS and ProtParam sites).
A
260,conjugate
=A
260,DNA
+A
260,Protein=ε260,DNA×b×c260,DNA+ε260,Protein×b×c260,Protein
A
280,conjugate
=A
280,DNA
+A
280,Protein=ε280,DNA×b×c280,DNA+ε280,Protein×b×c280,Protein
Human breast cancer cell lines BT-474, SK-OV-3, ZR-75-1 and MCF-7 were maintained at 37° C. in a humidified atmosphere containing 5% CO2 in RPMI 1640 (HyClone, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin solution. To detect HER2 using the assay, after treatment with trypsin, the cells were washed with PBS and resuspended in reaction buffer containing 80 pM Dynasore (dynamin inhibitor; ab120629; Abcam, United Kingdom) to adjust the concentration to 0.5×106 cells/mL. HER2 detection was performed using a PPR-based homologous assay.
After treatment with trypsin, the cells were washed twice with 1 mL cold fluorescence-activated cell sorting (FACS) buffer (PBS, 2% FBS) and incubated along with 100 nM trastuzumab on ice for 1 hour. Then, the cells were washed twice with cold FACS buffer and incubated on ice along with 10 ng/mL of a goat anti-human IgG (H+L) cross-adsorbed secondary antibody conjugated with Alexa Fluor 488 (A-11013; Invitrogen, Thermo Fisher, USA) for 1 hour. After washing, the cells were resuspended in 500 μL of cold FACS buffer and the cell surface fluorescence intensity was analyzed by FACS (BD FACSCalibur, BD Biosciences, USA).
The method for detecting a target substance according
to the present invention is fast and simple because it is performed by a one-step process including simultaneously adding four conjugates (a first DNA-first binder conjugate, a first DNA′-protease conjugate, a second DNA-second binder conjugate, and a second DNA′-zymogen conjugate) and a substrate specific to the enzyme source to a sample using proximity proteolysis. In addition, the detection is possible and high sensitivity is obtained even when the concentration of the target substance is less than one nanomole. In addition, the binders are linked via two ssDNAs, rather than directly binding to the protease and the enzyme source, thus eliminating the necessity to prepare the protease-first binder and enzyme source-second binder conjugates before mixing with the sample. Therefore, the present invention can be used in a variety of fields such as disease diagnosis and drug concentration monitoring and is highly versatile by repeatedly using the same ssDNA-protease conjugate and ssDNA-enzyme source conjugate, and detecting various biomarkers only by changing the binder. Also, the present invention can be used to detect post-translational modifications of proteins or epigenetic modifications of chromosomes at specific locations.
Although specific configurations of the present invention have been described in detail, those skilled in the art will appreciate that this description is provided to set forth preferred embodiments for illustrative purposes, and should not be construed as limiting the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the accompanying claims and equivalents thereto.
An electronic file is attached.
Number | Date | Country | Kind |
---|---|---|---|
10-2021-0032756 | Mar 2021 | KR | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/KR2022/003525 | 3/14/2022 | WO |